Insider Selling: VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sells $183,810.00 in Stock

Posted by on Jul 24th, 2026

VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) major shareholder Sardar Biglari sold 11,000 shares of the stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $16.71, for a total value of $183,810.00. Following the sale, the insider owned 3,538,961 shares of the company’s stock, valued at approximately $59,136,038.31. The trade was a 0.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

  • On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.70, for a total value of $45,908.30.
  • On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.71, for a total value of $109,166.43.
  • On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.73, for a total value of $20,260.03.

VanEck Biotech ETF Stock Performance

Shares of VanEck Biotech ETF stock opened at $204.03 on Friday. The company’s fifty day simple moving average is $194.35 and its 200-day simple moving average is $192.32. VanEck Biotech ETF has a 1 year low of $156.45 and a 1 year high of $212.54.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BBH. Segall Bryant & Hamill LLC acquired a new position in shares of VanEck Biotech ETF during the first quarter valued at about $881,000. Paragon Private Wealth Management LLC lifted its stake in shares of VanEck Biotech ETF by 5.3% in the first quarter. Paragon Private Wealth Management LLC now owns 15,368 shares of the company’s stock valued at $2,890,000 after buying an additional 775 shares during the period. Bank of America Corp DE grew its position in VanEck Biotech ETF by 44.3% during the first quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock worth $12,473,000 after buying an additional 20,375 shares in the last quarter. Royal Bank of Canada grew its position in VanEck Biotech ETF by 4.3% during the first quarter. Royal Bank of Canada now owns 13,843 shares of the company’s stock worth $2,603,000 after buying an additional 565 shares in the last quarter. Finally, Wealthfront Advisers LLC increased its stake in VanEck Biotech ETF by 27.0% during the first quarter. Wealthfront Advisers LLC now owns 7,004 shares of the company’s stock valued at $1,317,000 after acquiring an additional 1,491 shares during the period. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

(Get Free Report)

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.

Recommended Stories

Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.